eEF2K inhibits the aerobic glycolysis of lung cancer cells by the blockage of pyruvate kinase M2 isoform (PKM2) dimerization and inactivation of STAT3, leading to the impairment of tumor growth (Xiao et al., 2020). Here, EEF2K is linked to lung cancer.